(3R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine | 223463-20-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (3R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine
• 英文别名: (3R)-3-amino-1-ethyl-5-phenyl-3H-1,4-benzodiazepin-2-one
• CAS: 223463-20-5
• 化学式: C₁₇H₁₇N₃O
• 分子量: 279.341
• InChiKey: VTQRGYNHDRZXFO-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine 、 对硝基苯基氯甲酸酯 在 三乙胺 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead

  摘要：

  High-throughput screening of the Merck sample collection identified benzodiazepinone tetralin-spirohydantoin 1 as a CGRP receptor antagonist with micromolar activity. Comparing the structure of 1 with those of earlier peptide-based antagonists such as BIBN 4096 BS, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepinone piperidinyldihydroquinazolinone 7, CGRP receptor K-i=44 nM and IC50=38 nM. Compound 7 was orally bioavailabile in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.051

文献信息

• [EN] BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CGRP DE BENZODIAZEPINE
  申请人：MERCK & CO INC

  公开号：WO2005000807A3

  公开（公告）日：2006-01-05
• Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead
  作者：Theresa M. Williams、Craig A. Stump、Diem N. Nguyen、Amy G. Quigley、Ian M. Bell、Steven N. Gallicchio、C. Blair Zartman、Bang-Lin Wan、Kimberly Della Penna、Priya Kunapuli、Stefanie A. Kane、Ken S. Koblan、Scott D. Mosser、Ruth Z. Rutledge、Christopher Salvatore、John F. Fay、Joseph P. Vacca、Samuel L. Graham

  DOI：10.1016/j.bmcl.2006.02.051

  日期：2006.5

  High-throughput screening of the Merck sample collection identified benzodiazepinone tetralin-spirohydantoin 1 as a CGRP receptor antagonist with micromolar activity. Comparing the structure of 1 with those of earlier peptide-based antagonists such as BIBN 4096 BS, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepinone piperidinyldihydroquinazolinone 7, CGRP receptor K-i=44 nM and IC50=38 nM. Compound 7 was orally bioavailabile in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine. (C) 2006 Elsevier Ltd. All rights reserved.